Rifamycin

In the long term, we like the position of the company, especially if Santarus can hold on to Zegerid until either budesonide or rifamycin − or both − gets on the market. ❋ Zacks.com (2010)

XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. ❋ Unknown (2010)

At best, rifamycin SV MMX is still years from the market. ❋ Unknown (2010)

Vaccine to treat Pseudomonas pneumonia on way: Sanofi and KaloBios Xiaflex - new drug to treat clenched fingers Xiaflex from Auxilium Santarus to study new drug rifamycin SV MMX in travelers 'diarrhea Venus Remedies to launch Mebatic infusion to fight gastro intestinal infections in India H1N1 swine flu test kit Prodesse ProFlu-ST for rapid detection of pandemic virus gets emergency approval in US: Gen-Probe ❋ Unknown (2010)

III clinical testing of rifamycin SV MMX in patients with travelers 'diarrhea in the second quarter of 2010. ❋ Unknown (2010)

The company also possesses a phase III ready candidate in rifamycin SV MMX for traveler's diarrhea. ❋ Unknown (2010)

Santarus is also developing two late-stage lower GI product candidates, budesonide MMX® and rifamycin SV MMX®, for the U.S. market. ❋ Unknown (2010)

Santarus began Phase III clinical testing of rifamycin SV ❋ Unknown (2010)

Santarus expects to begin Phase III clinical testing of rifamycin SV MMX in patients with travelers 'diarrhea in the second quarter of 2010. ❋ Unknown (2010)

Santarus is also developing two late-stage GI product candidates, budesonide MMX (®) and rifamycin SV MMX (®), for the US market. ❋ Unknown (2010)

Meanwhile, pipeline candidates budesonide MMX and rifamycin SV MMX, if successfully developed, are not likely to hit the market before 2012. ❋ Unknown (2010)

The guidelines note that drug interactions between antiretroviral medications and rifamycin drugs can result in subtherapeutic levels of the anti-HIV drugs. ❋ Unknown (2009)

Updates on drug interactions that affect the use of rifamycin drugs for prevention and treatment of TB ❋ Unknown (2009)

Our plan is to continue to grow ZEGERID and GLUMETZA revenues to move the company toward sustained profitability, while funding the clinical development of our two late-stage, lower GI product candidates, budesonide MMX and rifamycin SV MMX. ❋ Unknown (2009)